This aberrant Axl activation was confirmed by others, who also reported that Axl not only modulates motility and invasion capacities of sorafenib-resistant HCC cells, but also its downregulation increases the sensitivity of sorafenib-naïve and sorafenib-resistant cells to this drug (114). Here, AXL is linked to hepatocellular carcinoma.